Teva Xtampza Settlement Brings Potential Three-Year Head Start
Suit In Delaware Court Settled With 2033 Date
Teva is lining up another complex ANDA product after agreeing to settle litigation with Collegium Pharmaceutical over the Israeli firm’s proposed generic version of Xtampza ER (oxycodone) extended-release capsules.
You may also be interested in...
Teva says it remains hopeful that it can resolve US price-fixing allegations “in a positive way” with the US Department of Justice, but acknowledges that the matter could go all the way to trial.
New and updated guidances are good news for ANDA sponsors, but timing – coming the day Sandoz announced a CRL for its Advair copy – underscores challenges that developers of complex generics face.
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.